Cellsway
Private Company
Funding information not available
Overview
Cellsway is a private, pre-revenue diagnostics company pioneering a microfluidic CTC liquid biopsy platform. Its integrated system combines a patented size-based enrichment device with proprietary downstream immunofluorescence assay panels to profile cancer biomarkers from blood. The company is currently conducting a 300-patient clinical study to optimize its workflow and has initiated commercial partnerships, such as with Omega Genetik in Turkey, signaling a transition towards market entry and validation.
Technology Platform
Integrated microfluidic liquid biopsy platform for the size-based enrichment, identification, and immunofluorescence-based characterization of Circulating Tumor Cells (CTCs) from blood.
Opportunities
Risk Factors
Competitive Landscape
Cellsway competes in the CTC isolation segment against companies like Menarini Silicon Biosystems (CellSearch) and Fluxion Biosciences, and more broadly against the dominant cfDNA liquid biopsy players (e.g., Guardant Health, Freenome). Its differentiation lies in a fully automated, rapid workflow designed for distributed service labs rather than central facilities.